This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Malignant melanoma (intraocular)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

These are primarily choroidal (85%) but may also affect the ciliary body (9%) and the iris (6%). The tumour is invariably unilateral.

Choroidal melanomas usually present with visual field loss or a loss of acuity if the macula is affected. Sometimes they may be discovered incidentally on examination. In time, the tumour infiltrates through Bruch's membrane and pushes the retina forward causing a retinal detachment. Untreated, this results in glaucoma and extension of the tumour, either through the sclera, or outside. Metastases are blood borne and most commonly affect the liver.

Iris tumours usually present with colour change of the iris or a deformity of pupil.

Fluorescein angiography may be helpful in establishing the diagnosis.

Choroidal melanomas may be treated by enucleation or for smaller tumours, by radiotherapy. The prognosis is excellent if the tumour is less than 10 mm diameter.

Iridectomy is advised for iris tumours which have invaded the iris root. Their prognosis is good, and the mortality rate is less than 1%.


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.